A company transforming drug discovery by integrating advanced Artificial Intelligence (AI), physics-based computational modeling, and extensive wet lab capabilities, TandemAIhas successfully completed a $22 million Series A extension funding round from both new and existing investors.

This latest capital infusion increases the total funds raised by the company since its founding in October 2021 to over $80 million. The investment represents a strong vote of confidence in TandemAI’s fully integrated, computation-first engine, which has been proven to significantly enhance the efficiency and success rates of pharmaceutical R&D. The company, which boasts a team of over 300 professionals, has already delivered more than ten high-value, highly differentiated drug candidates that are either currently in or soon to enter clinical development.

TandemAI's rapid success is further underscored by its partnership network of over 150 global clients, including four of the world’s top ten multinational pharmaceutical companies. The new funding will be strategically deployed to support the continued development of the company’s AI and computational physics-based models for multiple therapeutic modalities, as well as the expansion of its wet lab capacity to accommodate a rapidly growing client base.

Furthermore, the capital will help TandemAI capitalize on emerging opportunities in peptide and antibody-peptide conjugate discovery, following its recent strategic merger with Perpetual Medicines, which brought seasoned drug development expertise onto the team. The company’s core offering is its proprietary, AI-enabled SaaS platform, TandemViz™, which integrates cutting-edge computational modules with high-performance computing infrastructure, ensuring rapid dry-wet lab integration and streamlined data management across the entire drug development process, from target prediction to clinical candidate determination.